Header Logo

Connection

Francesca CONRADIE to Tuberculosis, Multidrug-Resistant

Back to Details
This is a "connection" page, showing publications Francesca CONRADIE has written about Tuberculosis, Multidrug-Resistant.
Francesca CONRADIE
Connection Strength
5,890
Tuberculosis, Multidrug-Resistant
  1. Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis. N Engl J Med. 2022 09 01; 387(9):810-823.
    View in: PubMed
    Score: 0,657
  2. Treatment of Highly Drug-Resistant Pulmonary Tuberculosis. Reply. N Engl J Med. 2020 06 11; 382(24):2377.
    View in: PubMed
    Score: 0,563
  3. High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen. Eur Respir J. 2018 12; 52(6).
    View in: PubMed
    Score: 0,509
  4. Prevalence and incidence of symmetrical symptomatic peripheral neuropathy in patients with multidrug-resistant TB. S Afr Med J. 2013 Oct 11; 104(1):24-6.
    View in: PubMed
    Score: 0,355
  5. Levofloxacin Preventive Treatment in Children Exposed to MDR Tuberculosis. N Engl J Med. 2024 Dec 19; 391(24):2315-2326.
    View in: PubMed
    Score: 0,193
  6. Patient and provider costs of the new BPaL regimen for drug-resistant tuberculosis treatment in South Africa: A cost-effectiveness analysis. PLoS One. 2024; 19(10):e0309034.
    View in: PubMed
    Score: 0,191
  7. Long-term efficacy and safety of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): extended follow-up of an open-label, multicentre, randomised, non-inferiority trial. Lancet Respir Med. 2024 Dec; 12(12):975-987.
    View in: PubMed
    Score: 0,190
  8. Validation of a Handheld 6-Lead Device for QT Interval Monitoring in Resource-Limited Settings. JAMA Netw Open. 2024 Jun 03; 7(6):e2415576.
    View in: PubMed
    Score: 0,186
  9. Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet/RESIST-TB consensus statement. Lancet Infect Dis. 2023 04; 23(4):e122-e137.
    View in: PubMed
    Score: 0,170
  10. Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial. Lancet. 2022 11 26; 400(10366):1858-1868.
    View in: PubMed
    Score: 0,166
  11. Proposed Linezolid Dosing Strategies to Minimize Adverse Events for Treatment of Extensively Drug-Resistant Tuberculosis. Clin Infect Dis. 2022 May 30; 74(10):1736-1747.
    View in: PubMed
    Score: 0,161
  12. Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the Philippines. BMJ Open. 2021 12 03; 11(12):e051521.
    View in: PubMed
    Score: 0,156
  13. Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study. Lancet Infect Dis. 2022 04; 22(4):496-506.
    View in: PubMed
    Score: 0,155
  14. Detection of isoniazid, fluoroquinolone, ethionamide, amikacin, kanamycin, and capreomycin resistance by the Xpert MTB/XDR assay: a cross-sectional multicentre diagnostic accuracy study. Lancet Infect Dis. 2022 02; 22(2):242-249.
    View in: PubMed
    Score: 0,154
  15. QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial. Lancet Infect Dis. 2021 07; 21(7):975-983.
    View in: PubMed
    Score: 0,148
  16. Responding to SARS-CoV-2 in South Africa: what can we learn from drug-resistant tuberculosis? Eur Respir J. 2020 07; 56(1).
    View in: PubMed
    Score: 0,142
  17. Standardised shorter regimens versus individualised longer regimens for rifampin- or multidrug-resistant tuberculosis. Eur Respir J. 2020 03; 55(3).
    View in: PubMed
    Score: 0,139
  18. Treatment of Highly Drug-Resistant Pulmonary Tuberculosis. N Engl J Med. 2020 03 05; 382(10):893-902.
    View in: PubMed
    Score: 0,138
  19. Willingness to Take Multidrug-resistant Tuberculosis (MDR-TB) Preventive Therapy Among Adult and Adolescent Household Contacts of MDR-TB Index Cases: An International Multisite Cross-sectional Study. Clin Infect Dis. 2020 01 16; 70(3):436-445.
    View in: PubMed
    Score: 0,137
  20. Feasibility of Identifying Household Contacts of Rifampin-and Multidrug-resistant Tuberculosis Cases at High Risk of Progression to Tuberculosis Disease. Clin Infect Dis. 2020 01 16; 70(3):425-435.
    View in: PubMed
    Score: 0,137
  21. Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial. Lancet Respir Med. 2019 12; 7(12):1048-1058.
    View in: PubMed
    Score: 0,135
  22. A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis. N Engl J Med. 2019 03 28; 380(13):1201-1213.
    View in: PubMed
    Score: 0,129
  23. Multidrug-resistant tuberculosis outbreak in South Africa. Lancet Infect Dis. 2019 02; 19(2):134-135.
    View in: PubMed
    Score: 0,127
  24. Frequency of Circulating CD4+Ki67+HLA-DR- T Regulatory Cells Prior to Treatment for Multidrug Resistant Tuberculosis Can Differentiate the Severity of Disease and Predict Time to Culture Conversion. Front Immunol. 2018; 9:2438.
    View in: PubMed
    Score: 0,126
  25. Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis. Appl Health Econ Health Policy. 2018 Feb; 16(1):43-54.
    View in: PubMed
    Score: 0,120
  26. Persistently high early mortality despite rapid diagnostics for drug-resistant tuberculosis cases in South Africa. Int J Tuberc Lung Dis. 2017 10 01; 21(10):1106-1111.
    View in: PubMed
    Score: 0,117
  27. A combination of baseline plasma immune markers can predict therapeutic response in multidrug resistant tuberculosis. PLoS One. 2017; 12(5):e0176660.
    View in: PubMed
    Score: 0,114
  28. A call to action: Addressing the reproductive health needs of women with drug-resistant tuberculosis. S Afr Med J. 2016 Mar 17; 106(4):30-1.
    View in: PubMed
    Score: 0,105
  29. Drug-drug interactions between bedaquiline and the antiretrovirals lopinavir/ritonavir and nevirapine in HIV-infected patients with drug-resistant TB. J Antimicrob Chemother. 2016 Apr; 71(4):1037-40.
    View in: PubMed
    Score: 0,104
  30. Risk factors for and timing of presumptive recurrent TB. Int J Tuberc Lung Dis. 2024 Nov 01; 28(11):527-533.
    View in: PubMed
    Score: 0,048
  31. Target regimen profiles for tuberculosis treatment. Bull World Health Organ. 2024 Aug 01; 102(8):600-607.
    View in: PubMed
    Score: 0,046
  32. Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial. Lancet Infect Dis. 2024 Sep; 24(9):1003-1014.
    View in: PubMed
    Score: 0,046
  33. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis. Eur Respir J. 2016 Feb; 47(2):564-74.
    View in: PubMed
    Score: 0,026
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.